Real-World’ Prolonged DAPT Use Associated With Reduced Benefits, and Greater Harm

 Prolonged use of dual antiplatelet therapy (DAPT) following PCI may be associated with reduced benefits and greater harms in “real-world” clinical practice in contrast to outcomes of the DAPT Study The study included 8,864 patients from the DAPT study and 568,540 registry patients. Longer-duration P2Y12 inhibitor therapy in the DAPT cohort was associated with a 1.01% decrease in-stent thrombosis, 1.9% decrease in major adverse cardiac and cerebrovascular events and a 2.27 decrease in MI but a 0.89% increase in moderate or severe bleeding. The study concludes that longer-duration DAPT may have more limited benefits and greater harms when applied broadly in a contemporary real-world population, thus highlighting the need to evaluate the applicability of cardiovascular clinical trials to contemporary real-world populations more broadly. Disclaimer: Lupin makes no representation or warranty of any kind, expressed or implied, regarding the accuracy, adequacy, validity, reliability, availability, or completeness of any scientific information shared by the HCP on the ­­­STAR UPDATE podcast. You should not allow the contents of this to substitute for your own medical judgment, which you should exercise in evaluating the information on this website.